Cytokinetics Inc.
About Cytokinetics Inc:
Cytokinetics, Inc. (Nasdaq: CYTK) is a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. A number of commonly used drugs and a growing body of research validate the role that the cytoskeleton plays in a wide array of human diseases. Cytokinetics focus on the cytoskeleton enables them to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease, fungal diseases and other diseases.
Cytokinetics has two drug candidates for the treatment of cancer, a drug candidate for the treatment of acute congestive heart failure and more than ten other research programs. Their most advanced drug candidate is SB-715992. Cytokinetics' second KSP inhibitor is SB-743921.
Product Pipeline Data for Cytokinetics
Oncology Program: SB-715992 for: Monotherapy -- Leukemia, solid tumors, non-small cell lung cancer, breast, ovarian, colorectal, prostate, head and neck, and melanoma.
More on Cytokinetics:
Key
Statistics for Cytokinetics
Basic
Chart for Cytokinetics